Okay, I just looked up the WSJ article from yesterday. The article is mainly about Amelio's ridiculous compensation but has a paragraph at the end commenting on the Friday SEC filing. Basically the WSJ just repeats the facts, the company's sales will slide through March, it will take another $30 million restructuring charge sometime in the next six months, and it faces pricing pressures from clones.
I've been expecting the lower revenues and the additional charge is a bit of a shock, but I don't see why the competition with the clones isn't fading, not increasing. From what I can tell, the competition since early November has been entirely in the low-end. I'd think UMAX is having a rougher time than Apple.
I'll mull this for a while. Meanwhile, AAPL's heading back up. 1/4 by 3/8.
Marc
PS--Alomex, good to have you back. Read the news.com article, if you haven't. |
